Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Ritlecitinib

Ritlecitinib

Ritlecitinib structure

Ritlecitinib 

structure
  • CAS No:

    1792180-81-4

  • Formula:

    C15H19N5O

  • Chemical Name:

    Ritlecitinib

  • Synonyms:

    1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one;1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2;PF-06651600;PF 06651600;PF06651600;1-[(2S,5R)-2-methyl-5(7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-1-piperidinly]-2-propen-1-one malonate,PF06651600;Ritlecitinib;2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-;1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one;Ritlecitinib (PF-06651600)

  • Categories:

    Pharmaceutical Intermediates  >  Bulk Drug Intermediates

Description

PF-06651600 is under investigation in clinical trial NCT02974868 (Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata).|Ritlecitinib is an orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.


Ritlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte’s Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.

Ritlecitinib Basic Attributes

285.34

285.15896025

210-077-2

2OYE00PC25

C161783

white to beige

Characteristics

1.272±0.06 g/cm3(Predicted)

H2O: 5mg/mL, clear (warmed)

13.03±0.50(Predicted)

room temp

Safety Information

WGK 3

|Warning|H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]|P201, P202, P281, P308+P313, P405, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Drug Information

1-(5-((7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Ritlecitinib Use and Manufacturing

Looking at the history of alopecia areata drug development, ritlecitinib is the second mature drug for treating alopecia areata. It is a kinase inhibitor. Unlike the first drug, Olumiant, ritlecitinib is approved not only for adult patients but also for adolescents aged 12 and above.

Recommended Suppliers of Ritlecitinib

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.